Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
1
8%
Ph phase_2
3
23%
Ph not_applicable
8
62%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
1(8.3%)
N/ANon-phased studies
8(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

92.3%

12 of 13 finished

Non-Completion Rate

7.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(12)
Terminated(1)

Detailed Status

Completed12
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
92.3%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (25.0%)
Phase 31 (8.3%)
N/A8 (66.7%)

Trials by Status

completed1292%
terminated18%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
PROCEDURE
Total Trials
13